How much does each drug of vosoritide cost, as well as purchase channels and patient cost reference instructions

Vosoritide is a peptide drug that targets specific signaling pathways in osteoblasts and is mainly used to treat dwarfism caused by achondroplasia (Achondroplasia). Its mechanism of action is to regulate the growth of chondrocytes by selectively activating the C type natriuretic peptide receptor (CNP-R) signaling pathway, thereby promoting long bone development and improving height growth rate, providing an innovative treatment method for children with chondrodysplasia.

In the domestic market, vorsolitide is not yet available on the market, so patients cannot obtain it directly through local hospitals or pharmacies for the time being. Due to the lack of marketing channels and medical insurance reimbursement policies, domestic patients who need to use the drug can currently only obtain the drug through overseas imports or participation in clinical trials. In reality, this increases the cost and difficulty of obtaining the drug, and also limits the popularity and application of the drug.

In overseas markets, the original drug of vosolitide has been launched. In the European market, the price of each drug is about 69,000 yuan. Since there are currently no generics or other alternative drugs, patients have to rely on original drugs, which makes long-term treatment more expensive. The specific dosage and frequency of use of each drug need to be determined based on body weight and doctor's prescription. It is usually a subcutaneous injection once a day. The medication regimen must strictly follow the guidance of medical professionals.

Overall, vorsolitide, as an innovative drug for the treatment of dwarfism, is expensive and currently unavailable in China. Patients and families need to fully evaluate the financial burden and treatment feasibility when considering use. In the future, if it is officially launched in China and enters the medical insurance system, it is expected to reduce the financial pressure on patients and improve drug accessibility. At present, patients should obtain overseas original drugs through formal channels, and conduct medication and efficacy monitoring under the guidance of professional doctors to ensure treatment safety and maximize clinical benefits.

Keyword tags: Vosolitide, achondroplasia, dwarfism,CNPReceptor agonist, price

Reference materials:https://pubmed.ncbi.nlm.nih.gov/34694597/